Retrospective validation of genomic biomarkers - What are the questions, challenges and strategies for developing useful relationships to clinical outcomes - Workshop summary

Pharmacogenomics Journal

Volumn 6, Issue 2, 2006, Pages 82-88

  Wang, S J ^a   Cohen, N ^b   Katz, D A ^c   Ruano, G ^d   Shaw, P M ^e   Spear, B ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c ABBOTT LABORATORIES   (United States)

^d Genomas Inc   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; ERLOTINIB; NEW DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DNA DETERMINATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENETIC ANALYSIS; GENOME ANALYSIS; HEART INFARCTION; HUMAN; HYPOTHESIS; MEDICAL RESEARCH; OUTCOMES RESEARCH; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEOMICS; QUALITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; STROKE; VALIDATION PROCESS; WORKSHOP;

CLINICAL TRIALS; DRUG DESIGN; DRUG INDUSTRY; ENDPOINT DETERMINATION; GENETIC MARKERS; GENOMICS; PHARMACOGENETICS; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33645061021     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500363     Document Type: Conference Paper

References (9)

1. McClellan M. FDA white paper 'Innovation and Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products', Issued March 16, 2004. http://www.fda.gov.
2. Tarceva (erlotinib) Labelling Package Insert 2004. Website http://www.tarceva.com/tarceva/patient/PI.jsp.
3. Code of Federal Regulations (CFR). Title 21, Section 314.126, adequate and well-controlled studies, applications for FDA approval to market a new drug. Website: http://www.convergentcosmetics.com/virtual_lab/ resources/CFR_21_Parts_1_to_799.htm.
4. Guidance for Industry. 'Providing clinical evidence of effectiveness for human drug and biological products' (May, 1998). http://www.fda.gov/cder/ guidance/1397fnl.pdf.
5. International Conference on Harmonization. Statistical Principles for Clinical Trials (ICH E-9), US Food and Drug Administration, DHHS, February 1998.
6. Lesko LJ, Salerno RA, Spear B, Anderson DC, Brazell C, Collins J et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: Report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol 2003; 43: 342-358.
7. Guidance for Industry. Pharmacogenomic Data Submission (2005). Website: http://www.fda.gov/cder/genomics/regulatory.htm.
8. Ruano G, Collins JM, Dorner AJ, Wang SJ, Guerciolini R, Huang SM. Pharmacogenomic data submissions to FDA: Clinical pharmacology case studies. Special report 4 of pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 2004; 5: 513-517.
9. Trepicchio WL, Williams GA, Essayan D, Hall ST, Harty LC, Shaw PM et al. Pharmacogenomic data submissions to FDA: Clinical case studies. Special report 5 of pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 2004; 5: 519-524.